Quantum BioPharma Ltd. Files September 2024 6-K
Ticker: QNTM · Form: 6-K · Filed: Sep 30, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, disclosure, filing
TL;DR
Quantum BioPharma filed its Sept 6-K, incorporating a press release from 9/27.
AI Summary
Quantum BioPharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on September 30, 2024, for the month of September 2024. This filing incorporates by reference a press release issued on September 27, 2024. The company is incorporated in A6 and its fiscal year ends on December 31.
Why It Matters
This filing indicates ongoing reporting activity for Quantum BioPharma Ltd., which is relevant for investors tracking the company's compliance and disclosures.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily incorporates a previously issued press release, indicating standard reporting procedures.
Key Numbers
- 001-39152 — SEC File Number (Identifies the company's filing history with the SEC.)
Key Players & Entities
- Quantum BioPharma Ltd. (company) — Registrant
- FSD Pharma Inc. (company) — Former company name
- September 27, 2024 (date) — Date of press release
- September 2024 (date) — Reporting period
- September 30, 2024 (date) — Filing date
- 333-276264 (other) — Registration statement file number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report information that Quantum BioPharma Ltd. has made or will make public, file, or distribute to its security holders, and to incorporate by reference a press release issued on September 27, 2024.
What was the former name of Quantum BioPharma Ltd.?
The former name of Quantum BioPharma Ltd. was FSD Pharma Inc., with a date of name change on March 27, 2019.
Which registration statement is this Form 6-K incorporated into?
This Form 6-K is incorporated by reference into the Registrant's Registration Statement on Form F-3, SEC File No. 333-276264.
What is the company's principal executive office address?
The company's principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
Does Quantum BioPharma Ltd. file annual reports under Form 20-F or 40-F?
Quantum BioPharma Ltd. files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F ☒'.
Filing Stats: 227 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-09-27 20:09:03
Filing Documents
- fsd_6k.htm (6-K) — 10KB
- fsd_ex991.htm (EX-99.1) — 21KB
- fsd_ex991img2.jpg (GRAPHIC) — 8KB
- 0001654954-24-012418.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: September 27, 2024 By: /s/ Donal Carroll Donal Carroll, Chief Financial Officer 3 EXHIBIT INDEX Exhibit Description Exhibit 99.1 Press Release dated September 27, 2024 4